Dan  Karlin net worth and biography

Dan Karlin Biography and Net Worth

Dan joined MindMed as Chief Medical Officer in February 2021 following MindMed’s acquisition of HealthMode, the company he co-founded and led as CEO.

Prior to HealthMode, he built and led clinical, informatics, and regulatory strategy for Pfizer’s Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. He previously served as founder and Chief Medical Officer at Column Health, a leading technology-enabled psychiatry and addiction practice. He is a strategic advisor to several pharmaceutical, biotech, and health technology companies. He is also a founding Advisor to the Digital Biomarkers Journal, co-founder and Board Chair of the Digital Medicine Society (DiMe), and was on the committee for Leadership for Digital Drug Development Tools at Critical Path Alzheimer’s Disease, MJFF, and Mental Health IT at the APA.

Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is a Fellow of the APA and the American Society of Addiction Medicine and an Assistant Professor of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.

What is Dan Karlin's net worth?

The estimated net worth of Dan Karlin is at least $5.86 million as of December 26th, 2024. Dr. Karlin owns 338,013 shares of Definium Therapeutics stock worth more than $5,864,526 as of February 10th. This net worth approximation does not reflect any other investments that Dr. Karlin may own. Additionally, Dr. Karlin receives a salary of $658,520.00 as Insider at Definium Therapeutics. Learn More about Dan Karlin's net worth.

How old is Dan Karlin?

Dr. Karlin is currently 44 years old. There are 5 older executives and no younger executives at Definium Therapeutics. The oldest executive at Definium Therapeutics is Dr. Miriam Halperin Wernli B.A., M.A., M.B.A., MBA, Ph.D., Executive President, who is 71 years old. Learn More on Dan Karlin's age.

What is Dan Karlin's salary?

As the Insider of Definium Therapeutics, Inc., Dr. Karlin earns $658,520.00 per year. The highest earning executive at Definium Therapeutics is Mr. Robert Barrow, CEO & Director, who commands a salary of $931,130.00 per year. Learn More on Dan Karlin's salary.

How do I contact Dan Karlin?

The corporate mailing address for Dr. Karlin and other Definium Therapeutics executives is One World Trade Center Suite 8500 New York, NY 10007 United States. Definium Therapeutics can also be reached via phone at 212 220 6633 and via email at [email protected]. Learn More on Dan Karlin's contact information.

Has Dan Karlin been buying or selling shares of Definium Therapeutics?

Dan Karlin has not been actively trading shares of Definium Therapeutics in the last ninety days. Most recently, Dan Karlin sold 6,643 shares of the business's stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $7.43, for a transaction totalling $49,357.49. Following the completion of the sale, the insider now directly owns 338,013 shares of the company's stock, valued at $2,511,436.59. Learn More on Dan Karlin's trading history.

Who are Definium Therapeutics' active insiders?

Definium Therapeutics' insider roster includes Robert Barrow (Chief Executive Officer and Board Director), Schond Greenway (CFO), David Gryska (Director), Dan Karlin (Insider), Daniel Karlin (Insider), Carrie Liao (CAO), and Mark Sullivan (Insider). Learn More on Definium Therapeutics' active insiders.

Are insiders buying or selling shares of Definium Therapeutics?

During the last twelve months, insiders at the sold shares 12 times. They sold a total of 163,667 shares worth more than $1,515,041.22. The most recent insider tranaction occured on December, 26th when insider Daniel Karlin sold 5,600 shares worth more than $73,640.00. Insiders at Definium Therapeutics own 2.3% of the company. Learn More about insider trades at Definium Therapeutics.

Information on this page was last updated on 12/26/2025.

Dan Karlin Insider Trading History at Definium Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/26/2024Sell6,643$7.43$49,357.49338,013View SEC Filing Icon  
9/25/2024Sell6,871$5.98$41,088.58344,656View SEC Filing Icon  
6/25/2024Sell6,925$7.22$49,998.50351,527View SEC Filing Icon  
3/25/2024Sell6,578$9.50$62,491.00358,452View SEC Filing Icon  
12/26/2023Sell6,774$3.63$24,589.62365,030View SEC Filing Icon  
9/25/2023Sell6,918$3.57$24,697.26371,804View SEC Filing Icon  
6/27/2023Sell6,783$3.20$21,705.60378,722View SEC Filing Icon  
3/1/2023Sell3,577$3.51$12,555.27260,505View SEC Filing Icon  
12/21/2022Sell1,211$2.69$3,257.59264,082View SEC Filing Icon  
10/27/2022Sell644$3.00$1,932.00265,293View SEC Filing Icon  
10/25/2022Sell541$2.81$1,520.21265,937View SEC Filing Icon  
9/26/2022Sell565$5.51$3,113.15267,118View SEC Filing Icon  
7/27/2022Sell9,856$0.69$6,800.644,033,264View SEC Filing Icon  
7/25/2022Sell8,361$0.69$5,769.094,043,120View SEC Filing Icon  
6/27/2022Sell26,238$0.70$18,366.604,051,481View SEC Filing Icon  
5/27/2022Sell9,555$0.82$7,835.104,077,719View SEC Filing Icon  
5/25/2022Sell8,242$0.77$6,346.344,087,274View SEC Filing Icon  
See Full Table

Dan Karlin Buying and Selling Activity at Definium Therapeutics

This chart shows Dan Karlin's buying and selling at Definium Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Definium Therapeutics Company Overview

Definium Therapeutics logo
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Read More

Today's Range

Now: $17.35
Low: $16.55
High: $17.40

50 Day Range

MA: $14.38
Low: $11.94
High: $18.23

2 Week Range

Now: $17.35
Low: $4.70
High: $18.70

Volume

829,525 shs

Average Volume

1,992,820 shs

Market Capitalization

$1.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57